Wells Fargo upgraded Relay Therapeutics (RLAY) to Overweight from Equal Weight with a price target of $13, up from $6. The firm believes the stock could work in 2026 on its data updates. Wells expects the RLY-2608 data to be competitive.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY: